5di PAOLO D, PASTORINO F, BRIGNOLE C, et al. Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment[J]. Tumori, 2008, 94(2): 246-253.
6TOMA S, TUCCI A, VILLANI G, et al. Liposomal doxorubiein (Caelyx) in advanced prelreated soft tissue sarcomas: a phase Ⅱ study of the Italian Sarcoma Group (ISG)[J]. Anticancer Res, 2000, 20(1B) : 485-491.
7SWENSON CE, BOLCSAK LE, BATIST G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D- 99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastalic breast cancer [J]. Anticancer Drugs, 2003, 14(3): 239-246.
8FORSSEN EA. The design and development of DaunoXome for solid tumor targeting in vivo[J]. Adv Drug Deliv Rev, 1997, 24(2-3): 133-150.
9GILL PS, ESPINA BM, MUGGIA F, et al. Phase Ⅰ/Ⅱ clinical and pharmacokinetic evaluation of liposomal daunorubicin [J]. J Clin Oncol, 1995, 13: 996.
10MANTRIPRAGADA S. A lipid based depot (DepoFoam technology) for sustained release drug delivery [J]. Prog Lipid Res, 2002, 41(5) : 392-406.
